BioSpace News Archive

Contributing to both the Cancer and Inflammation and Immunity Steering Committees

Independent practice association selects leading referral intelligence engine to drive referrals to low-cost, high-quality providers, improve outcomes, and increase profitability

USPTO issues sixth CRISPR-Cas9-related patent to University of California for genome editing and modulation of gene expression

Camurus announces that the leading drug dependence journal Addiction has published full results from a 48-week, open-label, global Phase 3 study of weekly and monthly Buvidal®, the first and only long-acting injection medicine to be approved for the treatment of opioid dependence in the EU and Australia.

DNA profiles generated on a MiSeq® system were critical evidence in landmark Dutch case.

Funding will support this registration study and rapid global availability of the vaccine against Chikungunya

To the benefit of both patients and health care consumers nationwide, a federal judge will hold an evidentiary hearing—the first of its kind—in what is known as a Tunney Act proceeding—to consider opposition to the pending $69 billion merger of Aetna and CVS Health Corp. that was voiced by friends of the court (amicus curiae), including AIDS Healthcare Foundation (AHF).

Caris Life Sciences® announced that Brian J. Brille, Vice Chairman of the Company, will present at the Jefferies 2019 Healthcare Conference on Friday, June 7, 2019, at 8:30 a.m. Eastern time.

Immunic, Inc. announced that Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present newly available preclinical data confirming IMU-935 as a highly potent inhibitor of both, RORt and dihydroorotate dehydrogenase, which was shown to lead to a strong synergism on the reduction of pro-inflammatory cytokine release.

Sage Therapeutics announced that the Company will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019 at 8:00 a.m. PDT in Palos Verdes, Cal.